Evidence map›Paper›PMID 29719777›Full record

ReviewActa pharmaceutica Sinica. B2018

Mesoporous silica nanoparticles for drug and gene delivery.

Yixian Zhou, Guilan Quan, Qiaoli Wu, Xiaoxu Zhang, Boyi Niu, Biyuan Wu, Ying Huang, Xin Pan, Chuanbin Wu

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Acta pharmaceutica Sinica. B, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 237 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
237citing papers in PubMed, 2 pooled it
28.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

237 citing papers in PubMed, 2 syntheses or guidelines pooled it, 680 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Mesoporous Silica Nanoparticles in Biomedicine: Advances and Prospects.Advanced materials (Deerfield Beach, Fla.) · 2026
    Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

177 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Yixian ZhouSchool of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China.
Guilan QuanSchool of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China.
Qiaoli WuZengcheng District People's Hospital of Guangzhou, Guangzhou 51006, China.
Xiaoxu ZhangQingdao Huanghai University, Qingdao 266427, China.
Boyi NiuSchool of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China.
Biyuan WuSchool of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China.
Ying HuangSchool of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China.
Xin PanSchool of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China.
Chuanbin WuSchool of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China.
Sun Yat-sen University · CNQingdao Huanghai University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mesoporous silica nanoparticles (MSNs) are attracting increasing interest for potential biomedical applications. With tailored mesoporous structure, huge surface area and pore volume, selective surface functionality, as well as morphology control, MSNs exhibit high loading capacity for therapeutic agents and controlled release properties if modified with stimuli-responsive groups, polymers or proteins. In this review article, the applications of MSNs in pharmaceutics to improve drug bioavailability, reduce drug toxicity, and deliver with cellular targetability are summarized. Particularly, the exciting progress in the development of MSNs-based effective delivery systems for poorly soluble drugs, anticancer agents, and therapeutic genes are highlighted.

Indexed as

AO, acridine orangeAPTES, 3-aminopropyltriethoxysilaneAPTMS, amino propyl trimethoxysilaneBCL-2, B-cell lymphoma-2BCS, Biopharmaceutical Classification SystemBio-TEM, biological transmission electron microscopyCancer therapyC dots, Cornell dotsCMC, critical micelle concentrationCPT, camptothecinCTAB, cetyltrimethyl ammonium bromideEPR, enhanced permeability and retentionFDA, Food and Drug AdministrationGene deliveryGI, gastrointestinalGNRs@mSiO2, mesoporous silica-encapsulated gold nanorodsLHRH, luteinising-hormone releasing hormoneMDR, multi-drug resistanceMesoporous silica nanoparticlesMRP1, multidrug resistance protein 1MSN-Dox-G2, Dox-loaded and G2 PAMAM-modified MSNsMSNs-HA, hyaluronic acid-conjugated MSNsMSNs, mesoporous silica nanoparticlesMSNs@PDA-PEG-FA, poly(ethylene glycol)-folic acid-functionalized polydopamine-modified MSNsMSNs-RGD/TAT, RGD/TAT peptide-modified MSNsMSNs-TAT, TAT peptide-modified MSNsMTT, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromideMultidrug resistanceNIR, near-infraredPAMAM, polyamidoaminePDEAEMA, poly (2-(diethylamino)ethylmethacrylate)PDMAEMA, poly(2-(dimethylamino)ethylmethacrylate)pDNA, plasmid DNAPEG400, polyethylene glycol 400PEI, polyethyleneimineP-gp, P-glycoproteinPLL, poly-l-lysinePoorly soluble drugPTX, paclitaxelQ-MSNs, quercetin encapsulated MSNsRGD, arginine-glycine-aspartateTAT, trans-activating transcriptorTMB, 1,3,5-trimethybenzene

Identifiers

PMID29719777
PMCPMC5926503
OpenAlexW2791845263

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.